NIDB-3101, a Novel Biparatopic Anti-Tau Antibody: Characterization of its Pharmacokinetics, Pharmacodynamics and Tolerability

View poster

The poster was presented at AAIC 2026

Authors: Nadia Anceriz (1), Susana Salgado-Pires (1), Roman Rösemann (2), Bruno Daubeuf (1), Adeline Lesnier (1), Laurence Chatel (1), Alizée Viandier (1), Pauline Lloveras (1), Eric Hatterer (1), Dmitry Shchelokov (3), Galina Saynukova (3), Oleg Demin Jr (3), Jean-Philippe Courade (4)

Affiliation: (1) Light Chain Bioscience - Novimmune SA, Geneva, Switzerland, (2) Granzer Regulatory Consulting & Services GmbH, Munich, Germany, (3) InSysBio CY Ltd, Limassol, Cyprus, (4) discoveric bio alpha Ltd, Pfäffikon, Schwyz, Switzerland

The poster includes mechanistic modeling results supporting the preclinical development and subsequent translation to humans of a next-generation anti-tau therapeutic candidate.